Literature DB >> 31432258

Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.

Eleonora Fiorenzato1, Angelo Antonini2, Valeria Camparini3, Luca Weis3, Carlo Semenza3,2, Roberta Biundo3.   

Abstract

Cognitive impairment is frequent in progressive supranuclear palsy (PSP) and less common in multiple system atrophy (MSA), but characteristics and progression compared with Parkinson's disease (PD) need to be properly defined. We evaluated 35 PSP with Richardson's syndrome (PSP-RS), 30 MSA as well as 65 age-, sex-, and education-matched PD with an extensive clinical and neuropsychological assessment, allowing Level II cognitive diagnosis. Eighteen PSP, 12 MSA and 30 PD had a second evaluation between 12 and 18 months (mean 15 months) after the first assessment. PSP performance at Montreal Cognitive Assessment (MoCA), verbal fluencies (phonemic and semantic tasks), Stroop test (Error and Time), Digit Span Sequencing (DSS), incomplete letters of Visual Object and Space Perception (VOSP) and Benton's Judgment of Line Orientation (JLO) performance were significantly poorer at baseline compared to PD and MSA. Executive, language and visuospatial abilities declined longitudinally in PSP, but not in PD and MSA. After 1.5 year, 16% of PSP converted to dementia. Our study provides evidence that cognitive progression is more severe and rapid in PSP-RS than PD and MSA. Further, we observed that MoCA, verbal fluency (particularly semantic), DSS and Benton's JLO are valuable tests to detect cognitive progression in PSP-RS and may be proposed as possible biomarker to assess efficacy of disease modification strategies.

Entities:  

Keywords:  Executive functions; Longitudinal study; Parkinson’s disease; Progressive supranuclear palsy; Verbal fluency; Visuospatial functions

Mesh:

Year:  2019        PMID: 31432258     DOI: 10.1007/s00702-019-02065-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  39 in total

1.  Trail making test: normative values from 287 normal adult controls.

Authors:  A R Giovagnoli; M Del Pesce; S Mascheroni; M Simoncelli; M Laiacona; E Capitani
Journal:  Ital J Neurol Sci       Date:  1996-08

2.  Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.

Authors:  N J Cordato; C Pantelis; G M Halliday; D Velakoulis; S J Wood; G W Stuart; J Currie; M Soo; G Olivieri; G A Broe; J G L Morris
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

Review 3.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

Review 4.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Authors:  Claire L Tomlinson; Rebecca Stowe; Smitaa Patel; Caroline Rick; Richard Gray; Carl E Clarke
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

Review 5.  Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Authors:  Bruno Dubois; David Burn; Christopher Goetz; Dag Aarsland; Richard G Brown; Gerald A Broe; Dennis Dickson; Charles Duyckaerts; Jefferey Cummings; Serge Gauthier; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Yoshikuni Mizuno; Ian G McKeith; C Warren Olanow; Werner Poewe; Cristina Sampaio; Eduardo Tolosa; Murat Emre
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

6.  Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Benjamin Mast; Kevin Duff; Tanis J Ferman; Irene Litvan
Journal:  Arch Clin Neuropsychol       Date:  2012-11-04       Impact factor: 2.813

Review 7.  Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease.

Authors:  Angie A Kehagia; Roger A Barker; Trevor W Robbins
Journal:  Lancet Neurol       Date:  2010-09-27       Impact factor: 44.182

8.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

Review 9.  Cognition in corticobasal syndrome and progressive supranuclear palsy: a review.

Authors:  James R Burrell; John R Hodges; James B Rowe
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  3 in total

1.  Quantification of Brain β-Amyloid Load in Parkinson's Disease With Mild Cognitive Impairment: A PET/MRI Study.

Authors:  Michela Garon; Luca Weis; Eleonora Fiorenzato; Francesca Pistonesi; Annachiara Cagnin; Alessandra Bertoldo; Mariagiulia Anglani; Diego Cecchin; Angelo Antonini; Roberta Biundo
Journal:  Front Neurol       Date:  2022-03-01       Impact factor: 4.003

2.  The Application of Deep Brain Stimulation for Progressive Supranuclear Palsy: A Systematic Review.

Authors:  Yafei Wen; Bin Jiao; Yafang Zhou
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

3.  Prospective CERAD Neuropsychological Assessment in Patients With Multiple System Atrophy.

Authors:  Fabian Maass; Peter Hermann; Daniela Varges; Sabine Nuhn; Christoph van Riesen; Ala Jamous; Niels K Focke; Manuel Hewitt; Andreas Leha; Mathias Bähr; Inga Zerr
Journal:  Front Neurol       Date:  2022-07-19       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.